In a regulatory filing, Becton Dickinson (BDX) disclosed that its director Jeffrey Henderson bought 1.5K shares of common stock on February ...

Citi analyst Joanne Wuensch maintained a Buy rating on Becton Dickinson (BDX – Research Report) today. The company’s shares closed last Friday ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson plans to break off its biosciences and diagnostic solutions business and focus on the medtech sector. The company said late Wednesday the split could take the form of a sale ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after the company reported fiscal Q1 EPS and announced ...

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and ...

Bengaluru: Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its life sciences unit on Wednesday, as the medical device maker aims ...

Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates.

Bengaluru: U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on ...

Shares of Becton Dickinson & Co. BDX slid 7.28% to $227.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083 ...